New test could change treatment for one in three patients with meningioma
Doctors often prescribe radiation along with surgery to treat a brain tumor called meningioma that originates in the protective membranes surrounding the brain. But side effects from radiation can be serious, including memory loss and cognitive decline, so it’s important to know which patients really need it.
Now, in findings published in Nature Medicine, scientists at UC San Francisco (UCSF) and Northwestern Medicine, in collaboration with 10 other medical centers, have found a highly accurate way to predict the best treatment for patients based on patterns of gene expression – which genes are turned on and off – in their tumors.
Screening tumors using this new approach could change the course of treatment for nearly one in three people with meningioma, the most common form of brain tumor diagnosed in 42,000 Americans each year. Unlike other brain tumors, meningiomas occur most often in female, Black and elderly patients.
The team concluded that just one in five patients with low-grade tumors (those less likely to regrow) may need radiation, while around two in five with higher-grade tumors may be better off without radiation, based on the results of the new gene-expression test.
“There’s been a lot of controversy in the field in terms of who should receive radiotherapy and who shouldn’t,” said Dr. David Raleigh, a radiation oncologist in the UCSF Brain Tumor Center and a senior author of the study, along with Stephen Magill, MD, PhD, assistant professor of Neurological Surgery at Northwestern University Feinberg School of Medicine. “Our biomarker takes the guessing game out of this and shows us which patients are likely to benefit from radiotherapy and which may get toxicity and possibly no benefit from radiation.”
From microscopes to molecules
Because meningiomas grow slowly, a patient may be unaware of their tumor until they start to experience neurological symptoms like numbness, vision loss or personality changes. There are no pharmaceutical treatments, so doctors rely on surgery to remove the tumor and radiation to prevent it from growing back. Doctors treat these tumors based on guidance from the World Health Organization, which stages them according to severity.
Pathologists currently classify meningiomas by looking at them under a microscope for features that indicate whether they may grow back, a system that is very good but not perfect. Patients with grade 1 tumors don’t usually receive radiation treatment if their tumors can be removed completely during surgery. Yet approximately 20 percent of the time, the tumors recur. Those with grade 2 and 3 tumors, which are much more aggressive and more likely to grow back after surgery, are often treated with radiation after surgery. It has been unclear how many of these patients, particularly those with grade 2 tumors, actually need radiation treatment.
Raleigh, along with Magill and lead author William Chen, MD, decided to look at classifying tumors according to which of their genes are turned on and off, thereby offering clues to how aggressive they might be.
“Gene-expression tests like this, that analyze a small number of genes at a time, are widely available for breast, prostate and some other cancers, and they’ve proven to be a very accurate and inexpensive alternative to other types of tests,” said Chen.
How to turn guesses into answers
Raleigh and Chen and their multidisciplinary team suspected that gene expression could more accurately point out the patients who would be helped by radiotherapy. Using samples from 1,856 meningioma patients at 12 medical centers in the U.S., Europe and Hong Kong, Raleigh’s team came up with a set of 34 genes whose gene expression patterns had the potential to predict whether a tumor would return.
One-fifth of the grade 1 tumors – the same number that grow back after surgery – expressed the patterns that Raleigh’s team found could predict a tumor’s regrowth. This fraction of patients may benefit from radiation. The investigators also found that two-fifths of patients with grade 2 and 3 tumors did not have a recurrence, and this, too, could be predicted by the tumor’s gene expression.
“When to proceed with additional surgery, radiotherapy or simply to observe a small residual meningioma is not always clear,” said Magill, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “This test adds information that can let us tailor our surgical and radiation approach to provide the best outcome for each patient and maximize both quality and quantity of life.”
The team’s next step is to test the approach in two clinical trials currently being developed.
This study was supported by National Institutes of Health grants P50 CA221747 and F32 CA213944, the Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Cancer Center and the Northwestern University NUSeq Core Facility.
